Loading
Insulin Placebo / Alzheimer Disease / Insulin · Phase 2 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 2 trial evaluating the safety and effects of empagliflozin and insulin as adjuncts to anti-amyloid therapy in early Alzheimer's disease. No results are yet available; the registry record shows only study design and planned primary endpoint (treatment-related serious adverse events at 6 months).
Phase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Alzheimer Disease; age from 55 Years; to 85 Years. Intervention: Insulin and Empagliflozin Matching Placebo; Empagliflozin and Insulin Matching Placebo; Double Placebo. Compared with: Insulin Placebo and/or Empagliflozin Placebo. n = 30. 1 site: United States.
This is a planned Phase 2 trial evaluating the safety and effects of empagliflozin and insulin as adjuncts to anti-amyloid therapy in early Alzheimer's disease. No results are yet available; the registry record shows only study design and planned primary endpoint (treatment-related serious adverse events at 6 months).
Primary endpoint is safety (adverse events), not efficacy or cognitive outcomes.
The source did not state who this applies to in practice.
This is a Phase 2 interventional trial registered but not yet recruiting, with no results posted; it represents early-phase work to evaluate safety and tolerability of adjunctive therapies in Alzheimer's disease.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07756294). This is a study registration, not published results. Lead sponsor: Wake Forest University Health Sciences. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 30 participants (ESTIMATED). Conditions: Alzheimer Disease. Interventions: DRUG: Empagliflozin; DRUG: Insulin; DRUG: Insulin Placebo; DRUG: Empagliflozin Placebo. Primary outcome measures: Number of treatment-related serious adverse events , Month 6. Brief summary: The purpose of this study is to find out what effects (good and bad) the study medications (insulin or Empagliflozin) have on adults with mild memory impairment or early Alzheimer's disease who are clinically prescribed an anti-amyloid therapy compared to placebo.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.